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Abstract
This commentary describes the contributions of a Dutch pharmacist who contributed in a unique manner to the
development of community pharmacy practice in Europe, to the evolution of practice-based research and to its
publication. With an interest in pharmaceutical care and in clinical pharmacy, Dr. van Mil changed practice and
policy in Europe over the last decades in a very visible way, here documented through a summary of some of his
main written contributions. We write this to honour his memory and contribute to the preservation of his legacy.
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The first reference to pharmaceutical care dates to 1975
[1], and successive definitions and operationalisation of
the term have continued across the world. However,
many of these were largely descriptive or pilot studies,
with little impact on practice or simply refinements of
terminology which did not transfer into policy which is
essential to lead to changes in the scope of practice of
pharmacists working in various health care settings.
A pragmatic approach, a strong character and a drive
to make the world a better place are some of the phrases
that could be used to describe Dr. Foppe van Mil, who
died on 18 July 2020. This commentary summarises the
most relevant achievements of a unique career that has
had an impact on the practice, research or policy relat-
ing to pharmacy across the world, either working on his
own or, more often, collaboratively with academic or
practice-based teams. Table 1 summarises many of the
projects with which Dr. van Mil was associated alongside
some key publications that influenced practitioners, re-
searchers and policy-makers, including his PhD thesis
which was a landmark for pharmacy practice in the
Netherlands, expanding its impact to many other coun-
tries [2].
He was involved in the first two pharmaceutical care
research projects in Europe; in the Asthma Intervention
Project (TOM), he was a postgraduate student, and in
the Care of the Elderly study (OMA), he was a leading
member of the research team [3, 6]. Both projects took a
holistic approach to patient care and involved inter-
national collaboration, two aspects that were characteris-
tic of Foppe’s conception of research. The major
influence on Foppe’s research involvement, and on his
influence on his colleagues, was his experience and ex-
pertise as a community pharmacist; this made him very
practical but also very demanding, because for him, re-
search was about, and for, the benefit of patients. His
reputation reached all countries, and even countries
recognised as having an advanced practice, including the
UK, benefited from visiting his practice in the
Netherlands [21].
Foppe had a very visible contribution to the dissemin-
ation of research and pharmacy practice, by his various
attributes and activities. He was an educator, but a prac-
tical one, who once committed, would work tirelessly to
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Table 1 Summary of practice, research projects and recognitions that have impacted pharmaceutical care practice or policy





TOM is a model for increasing
pharmacists’ role in primary
health care, based on a continuous
quality improvement system applied
to PhC to detect, prevent and resolve
DRPs in asthma patients. This project
was conducted as a controlled
intervention study (grouped at the
pharmacy level) and various outcomes
were measured to assess the impact of






These controlled intervention studies
had a huge impact on implementing
pharmacy practice research at the
university level in many countries.
Furthermore, results achieved led to
recognise pharmacist in DMPs and
clinical practice guidelines. Today, there
are specific programmes, often
remunerated, for pharmacists to support
inhaled medication used, namely in






Study of the effect of PhC in the elderly
(> 65 years) using 4 or more different
drugs and living independently.
Designed as a controlled study with
randomisation at the pharmacy level and
involved 1290 intervention patients
(selected in 104 pharmacies) and 1164
controls (selected from 86 pharmacies).
Outcomes measured included HRQoL,
patient satisfaction and knowledge,
provider satisfaction (GP and pharmacist),




Republic of Ireland, The
Netherlands
This was a landmark study as it was the
first multicentred study in European
community pharmacies. It was influential
in the field of pharmacy practice research.
[2, 3, 6]
Review article Discusses the concept of PhC care from
a European perspective and clarifies the
status of PhC research and
implementation. It discusses if PhC can
be part of the practice of pharmacy.
Europe It suggests changes in the pharmacy
curriculum so that pharmacists can
acquire new knowledge and skills. It
encourages countries to standardise
procedures adopted to guarantee every
patient receives PhC.
[7]
Review article Describes European developments in the
implementation of and research into
PhC, focusing on the community
pharmacy.
Europe Paper by invitation of the Harvard
Health Policy Review (USA).
[8]
Opinion paper Establishes the need and the rationale
for using a classification of DRPs to avoid
negative consequences for patients.
Germany Motivated the adoption of such
classifications in pharmacy practice




This sequence of publications establishes
the foundations for understanding
concepts of PhC, clinical pharmacy and
medication review, highlighting the
boundaries and similarities between
concepts, while reflecting the evolution
in practices.
Worldwide, with a special
focus in Europe
These definitions are used by academics
and researchers worldwide to support
teaching and educational activities.
[10–13]
Research paper Development of a PCNE-DRP
classification.
World Currently being used in Belgium, China,
Germany, Ghana, Norway, Poland,
Portugal, Serbia, Slovenia, Spain,
Sweden, and Taiwan.
[14–16]
Review paper Describes the healthcare system context,
pharmacy practice and range of services
offered in pharmacies in the Netherlands.
The Netherlands Used widely as reference to frame
various research or practice based studies
undertaken in this counrty
[17]
Review paper Describes the healthcare system context,
pharmacy practice and range of services
offered in pharmacy in Peru.
Peru (South America) Used widely as reference to frame various
research or practice based studies
undertaken in this counrty
[18]
Research paper Describes the healthcare system context,
pharmacy practice and range of services
offered in pharmacy in Europe.
Europe Provides a framework for countries to
benchmark themselves against each
other.
[19]
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deliver high quality. He was involved for many years in
the Programme Committee for the Continuing Educa-
tion Programme organised by the Community Pharmacy
Section of the International Pharmaceutical Federation
(FIP), through which annual sessions were held as pre-
satellite meetings. These sessions aimed at the continu-
ous professional development of pharmacists, particu-
larly in the area of pharmaceutical care, and have led to
the improvement of knowledge and practice skills of
community pharmacists [22]. The aims, development
and impact measurements of this programme were pub-
lished subsequently [23]. FIP and the World Health
Organization (WHO) collaborated to deliver a course on
pharmaceutical care in Uruguay and other Latin Ameri-
can countries and chose Foppe to do this. He used a
train-the-trainer model, in which theory-based sessions
were followed by visits to the settings where the trainers
practised to better understand their reality and adapt the
learnings to their needs.
Two of the main vehicles for the advancement and
dissemination of knowledge in the field of pharmaceut-
ical care in Europe are the European Society of Clinical
Pharmacy (ESCP) and the Pharmaceutical Care Network
Europe (PCNE). As a member of ESCP, Foppe delivered
workshops and lectures over many years and helped to
promote research through his contributions to the Com-
munication Committee. His unique contribution was co-
founding the PCNE (in 1994), and he was truly its back-
bone; irrespective of the challenges, whether organisa-
tional, fiscal or philosophical, Foppe persevered and his
belief in the value of PCNE and consequently sustained
everyone in it. The definition of pharmaceutical care, the
classification of drug-related problems and the concep-
tion of medication reviews all depended on Foppe’s ini-
tiative, determination and implementation. In addition
through national organisations, such as the “Förderinitia-
tive Pharmazeutische Betreuung” (Foundation Pharma-
ceutical Care) in Germany and at national pharmacy
conferences, for example, in Poland [24] and at special
occasions such as the award ceremony of the Royal
Pharmaceutical Society of Great Britain, Foppe was an
invited and valued contributor.
Foppe van Mil was an extraordinary person in the
Dutch pharmacy practice space and beyond. Always
vocal, always committed to innovation for the well-being
of patients and public health. He was a very straightfor-
ward, yet unorthodox person, who combined in a very
original and appealing manner practice and academic
work, at the University of Groningen. His drive to make
a difference, both in teaching and in research, was amaz-
ing and has always been well acknowledged. He was a
recipient of the Innovation Prize of the Royal Dutch As-
sociation of Pharmacists (KNMP), a unique signature of
excellence and leadership. This public recognition of in-
novative practice with visible benefits for patients con-
tributed to further dissemination of the concept of
pharmaceutical care and its implementation in practice
there [2]. But many other institutions and organisations
have publicly recognised him for his contribution lead-
ing to the advancements in research and practice. In
Spain, during the first International Congress of
Pharmaceutical Care (Atención Farmacéutica, San Se-
bastian 1999), he received together with Doug Hepler
and Linda Strand (both from the USA) the Pharmaceut-
ical Association of Gipuzkoa Award, as the judges con-
sidered these three individuals were, at that time, those
with the most significant contributions to the advance-
ment of pharmaceutical care internationally and whom,
as such, stimulated the move to further the concept of
pharmaceutical care in Spain, leading to its recognition
and establishment in the law some years later.
In addition to Foppe’s contribution to the dissemin-
ation of research and practice innovation to researchers
and pharmacy practitioners through his lectures and
workshops, he made a very significant contribution in
knowledge translation through his efficient and effective
editorship of the International Journal of Clinical Phar-
macy (IJCP). Throughout his time as editor-in-chief, he
encouraged students and practitioners to publish their
work. This journal, originally named Pharm. Weekblad
Table 1 Summary of practice, research projects and recognitions that have impacted pharmaceutical care practice or policy
(Continued)
Title Brief description Countries involved Impact References
Research paper Describes the medication review
practices in Europe, implementation and
remuneration models associated.
Europe Provides an assessment of the
implementation of medication review in
Europe, enabling benchmark and analysis
of the strong points of some of the
countries described in more detail.
[20]
Editor-in-Chief
of the Int J Clin
Pharm
Published high-quality manuscripts that
enhanced the visibility of pharmaceutical
care and clinical pharmacy in various
countries of the world.
Worldwide These publications have
provided evidence-based practice
to motivate policy changes in many
countries, including in some cases
changes in the scope of practice or






Alves da Costa et al. Journal of Pharmaceutical Policy and Practice           (2020) 13:51 Page 3 of 5
– Scientific Edition, which was a scientific publication,
became known first, as Pharmacy World & Science
(PWS), and then in 2010, was renamed to IJCP. His
work in this regard was transformative and leads to the
remoulding of the journal into one with a substantial
international impact.
Foppe was a great supporter of evidence-informed
pharmaceutical policy at a global level. In 2009, he
helped publish a key editorial in “Pharmacy World and
Science” regarding the starting of the journal “Southern
Med Review”, later renamed as “Journal of Pharmaceut-
ical Policy and Practice”, as he believed there was a pau-
city of journals focused on pharmaceutical policy, which
were needed to complement the more practice-based
ones [25].
At a later stage of his career, he edited a book aimed
at helping practitioners worldwide to implement
pharmaceutical care. This was indeed the main aim of
his life, to transform standard pharmacy practice, or
usual care as it is often called in randomised controlled
trials, into pharmaceutical care and make this advanced
way of constantly optimising medication usual practice.
In this book, he gathered more than 40 worldwide re-
puted authors and covered all aspects believed to be es-
sential for practice implementation, from disease-specific
to health care setting-specific, to country-specific and of
course not forgetting about university education and
continuous professional development [26].
He will be greatly missed by all his friends, colleagues
and followers throughout the world.
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